R. Dewar, A. Andea, J. Guitart, D. Arber, and L. Weiss, Best Practices in Diagnostic Immunohistochemistry: Workup of Cutaneous Lymphoid Lesions in the Diagnosis of Primary Cutaneous Lymphoma, Archives of Pathology & Laboratory Medicine, vol.139, issue.3, pp.338-50, 2015.
DOI : 10.5858/arpa.2014-0018-CP

F. Grange, P. Joly, C. Barbe, M. Bagot, S. Dalle et al., Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France, JAMA Dermatology, vol.150, issue.5, pp.535-576, 2014.
DOI : 10.1001/jamadermatol.2013.7452

F. Grange, T. Petrella, M. Beylot-barry, P. Joly, D. Incan et al., Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas, Blood, vol.103, issue.10, pp.3662-3670, 2004.
DOI : 10.1182/blood-2003-08-2726

C. Hans, D. Weisenburger, T. Greiner, R. Gascoyne, J. Delabie et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-82, 2004.
DOI : 10.1182/blood-2003-05-1545

J. Hoefnagel, M. Mulder, E. Dreef, P. Jansen, S. Pals et al., Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma, Modern Pathology, vol.19, issue.9, pp.1270-1276, 2006.
DOI : 10.1038/modpathol.3800650

W. Kempf, D. Kazakov, and C. Mitteldorf, Cutaneous lymphomas: an update. Part 2: Bcell lymphomas and related conditions. The American Journal of dermatopathology, pp.197-208, 2014.

L. Koens, W. Zoutman, P. Ngarmlertsirichai, G. Przybylski, P. Grabarczyk et al., Nuclear Factor-??B Pathway???Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.134, issue.1, pp.290-292, 2014.
DOI : 10.1038/jid.2013.265

V. Ngo, R. Young, R. Schmitz, S. Jhavar, X. W. Lim et al., Oncogenically active MYD88 mutations in human lymphoma, Nature, vol.206, issue.7332, pp.115-124, 2010.
DOI : 10.1038/nature09671

A. Pham-ledard, M. Beylot-barry, C. Barbe, M. Leduc, T. Petrella et al., High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type, JAMA Dermatology, vol.150, issue.11, 2014.
DOI : 10.1001/jamadermatol.2014.821

J. Rovira, K. Karube, A. Valera, D. Colomer, A. Enjuanes et al., MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome, Clinical Cancer Research, vol.22, issue.11, 2016.
DOI : 10.1158/1078-0432.CCR-15-1525

N. Senff, J. Hoefnagel, P. Jansen, M. Vermeer, J. Van-baarlen et al., Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO???EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers, Journal of Clinical Oncology, vol.25, issue.12, pp.1581-1588, 2007.
DOI : 10.1200/JCO.2006.09.6396

N. Senff, E. Noordijk, Y. Kim, M. Bagot, E. Berti et al., European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas, Blood, vol.112, issue.5, pp.1600-1609, 2008.
DOI : 10.1182/blood-2008-04-152850

R. Willemze, E. Jaffe, G. Burg, L. Cerroni, E. Berti et al., WHO-EORTC classification for cutaneous lymphomas, Blood, vol.105, issue.10, pp.3768-85, 2005.
DOI : 10.1182/blood-2004-09-3502

W. Wilson, R. Young, R. Schmitz, Y. Yang, S. Pittaluga et al., Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, Nature Medicine, vol.21, issue.8, pp.922-928, 2015.
DOI : 10.1200/JCO.2006.09.2403